Rifaximin for preventing episodes of overt hepatic encephalopathy

  • Technology appraisal guidance
  • TA337
  • Published: 
Download guidance (PDF)

6 Review of guidance

6.1 The guidance on this technology will be considered for review 3 years after publication. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
March 2015

  • National Institute for Health and Care Excellence (NICE)